Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Presentation TCT 2024

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

Presenter: Brian Lindman

October 30, 2024

Presentation TCT 2024

CON: Too Early or Too Risky

Presenter: Kevin Bainey

October 29, 2024

Presentation TCT 2024

PRO: Time is Now: Targeting Acute Inflammation and Residual Inflammatory Risk

Presenter: Vijay Kunadian

October 29, 2024

Presentation TCT 2024

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Presenter: Deepak Bhatt

October 29, 2024

Presentation TCT 2024

Putting it Together: New Systems of Care to Optimize Risk Factors Targets

Presenter: Amit Khera

October 29, 2024

Presentation TCT 2024

Lipid-Lowering Therapies for High-Risk Patients: Act Early and Target Aggressively

Presenter: Marc Bonaca

October 28, 2024

Presentation TCT 2024

TCT 28: Target Vessel Revascularization and Amputation After Chronic Limb-Threatening Ischemia Across Race Among Medicare Beneficiaries

Presenter: Joseph Kim

October 27, 2024

Presentation Interventional Complications 2024

Is Carotid Access a Percutaneous Target?

Presenter: James McCabe

August 02, 2024

Presentation NY Valves 2024

A New Class of TAVR, A New Design Target

Presenter: Christopher Meduri

June 05, 2024

Presentation ACC 2024

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

Presenter: David E. Kandzari

April 08, 2024

Presentation THT 2024

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

Presenter: Thomas Hanff

March 06, 2024

Advertisement

Impact of Delays in Diagnosis and Treatment: Join the AHA TARGET AS Program!

CON: Too Early or Too Risky

PRO: Time is Now: Targeting Acute Inflammation and Residual Inflammatory Risk

Role of Inflammation in Coronary Heart Disease: Why Does it Matter

Putting it Together: New Systems of Care to Optimize Risk Factors Targets

Lipid-Lowering Therapies for High-Risk Patients: Act Early and Target Aggressively

TCT 28: Target Vessel Revascularization and Amputation After Chronic Limb-Threatening Ischemia Across Race Among Medicare Beneficiaries

Is Carotid Access a Percutaneous Target?

A New Class of TAVR, A New Design Target

Effect of Alcohol-mediated Renal Denervation on Blood Pressure in the Presence of Antihypertensive Drugs: 3-month Primary Results From the Target BP I Randomized Trial

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content